Thomas Müller
#180,769
Most Influential Person Now
Researcher
Thomas Müller's AcademicInfluence.com Rankings
Thomas Müllercomputer-science Degrees
Computer Science
#11413
World Rank
#12092
Historical Rank
Machine Learning
#5227
World Rank
#5293
Historical Rank
Artificial Intelligence
#5633
World Rank
#5715
Historical Rank
Database
#8440
World Rank
#8834
Historical Rank
Download Badge
Computer Science
Why Is Thomas Müller Influential?
(Suggest an Edit or Addition)Thomas Müller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. (1998) (2074)
- Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. (2005) (576)
- Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype (1999) (300)
- Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. (2007) (180)
- Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7) (2004) (138)
- Familial parkinsonism with synuclein pathology (2001) (118)
- Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. (2013) (100)
- Genetic analysis of immunomodulating factors in sporadic Parkinson's disease (2000) (95)
- Drug therapy in patients with Parkinson’s disease (2012) (88)
- Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease (2015) (82)
- Photoreceptor layer thinning in idiopathic Parkinson's disease (2014) (82)
- Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers (2001) (76)
- α-Synuclein in Parkinson’s disease: causal or bystander? (2019) (71)
- Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease (2004) (69)
- Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control (2011) (62)
- Caries and periodontal disease in patients with Parkinson's disease. (2011) (62)
- Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease (2010) (59)
- Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. (2007) (58)
- Malnutritional neuropathy under intestinal levodopa infusion (2012) (57)
- Targeting repulsive guidance molecule A to promote regeneration and neuroprotection in multiple sclerosis. (2015) (56)
- Fibrosis associated with dopamine agonist therapy in Parkinson's disease. (2003) (53)
- Response Monitoring in De Novo Patients with Parkinson's Disease (2009) (53)
- Neuropathy in Parkinson’s Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs (2013) (53)
- Classification of advanced stages of Parkinson’s disease: translation into stratified treatments (2017) (51)
- Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders (2000) (50)
- Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease (2006) (46)
- Use of monoamine oxidase inhibitors in chronic neurodegeneration (2017) (46)
- Elevation of total homocysteine levels in patients with Parkinson’s disease treated with duodenal levodopa/carbidopa gel (2011) (44)
- Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical–pharmacological aspects (2018) (44)
- Valbenazine granted breakthrough drug status for treating tardive dyskinesia (2015) (43)
- Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease (2017) (42)
- Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease (2010) (41)
- Motor complications, levodopa metabolism and progression of Parkinson's disease (2011) (38)
- Homocysteine levels after acute levodopa intake in patients with Parkinson's disease (2009) (37)
- Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease (2013) (37)
- Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders. (2000) (36)
- Clinical Pharmacokinetics and Pharmacodynamics of Safinamide (2017) (35)
- Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. (2007) (35)
- Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease (2013) (35)
- Mutation analysis of the neurofilament M gene in Parkinson's disease (2003) (34)
- Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease (2017) (31)
- Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity (2014) (31)
- Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease (2016) (30)
- Cysteinyl‐glycine reduction as marker for levodopa‐induced oxidative stress in Parkinson's disease patients (2011) (29)
- Cysteine elevation in levodopa‐treated patients with Parkinson's disease (2009) (29)
- Children with multiple sclerosis should not become therapeutic hostages (2016) (26)
- Dynamics of Parkinson’s Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers (2019) (25)
- Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease (2020) (25)
- Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion (2012) (25)
- Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications (2013) (25)
- Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. (2002) (24)
- Tolcapone addition improves Parkinson’s disease associated nonmotor symptoms (2014) (24)
- Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. (2015) (23)
- Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference (2009) (22)
- Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease (2017) (21)
- A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson’s disease patients (2008) (21)
- Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease (2003) (21)
- Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. (2010) (20)
- Current status of safinamide for the drug portfolio of Parkinson’s disease therapy (2013) (20)
- Neuropsychological effects of deep brain stimulation for Parkinson's disease (2013) (20)
- Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition (2014) (19)
- The safety of istradefylline for the treatment of Parkinson’s disease (2015) (19)
- Pain Perception, Pain Drug Therapy and Health Status in Patients with Parkinson’s Disease (2011) (18)
- Peripheral COMT inhibition prevents levodopa associated homocysteine increase (2009) (18)
- Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease (2012) (18)
- Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease (2017) (17)
- Safinamide: an add-on treatment for managing Parkinson’s disease (2018) (17)
- Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease (2014) (17)
- Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia (2019) (17)
- Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status (2019) (16)
- Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. (2000) (16)
- Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. (2010) (16)
- The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease: (2010) (16)
- New small molecules for the treatment of Parkinson's disease (2010) (16)
- An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson’s disease (2018) (16)
- Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease (2007) (16)
- Analysis of the parkin deletion in sporadic and familial Parkinson's disease (1999) (15)
- Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (15)
- Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson’s disease (2006) (14)
- Workshop IV: Drug treatment guidelines for the long-term management of Parkinson's disease (2000) (14)
- Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease (2018) (14)
- Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology (2019) (13)
- Meta-analysis of Placebo-controlled Clinical Trials of Safinamide and Entacapone as Add-on Therapy to Levodopa in the Treatment of Parkinson's Disease (2015) (13)
- Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa® therapy (2013) (13)
- Cholinergic-adrenergic balance: Part 2. Relationship between drug sensitivity and personality (1990) (13)
- Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia (2019) (13)
- Long-term management of Parkinson’s disease using levodopa combinations (2018) (13)
- SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease. (1997) (12)
- Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients (2014) (12)
- Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study (2020) (12)
- Landscape of pain in Parkinson’s disease: impact of gender differences (2018) (12)
- Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients (2015) (12)
- Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review (2020) (11)
- Hypomethylation in Parkinson's disease: An epigenetic drug effect? (2016) (11)
- Evaluation of the gamma-synuclein gene in German Parkinson's disease patients. (2001) (11)
- Diadochokinetic movements differ between patients with Parkinson’s disease and controls (2010) (11)
- Comparison of gait training versus cranial osteopathy in patients with Parkinson's disease: a pilot study. (2013) (11)
- Vitamin D rise enhances blood perfusion in patients with multiple sclerosis (2019) (11)
- Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson’s disease (2008) (10)
- Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease (2007) (10)
- Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson’s disease (2011) (10)
- Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations (2013) (10)
- Self-perception and determinants of color vision in Parkinson’s disease (2018) (9)
- Investigational agents for the management of Huntington’s disease (2017) (9)
- Perspective: Treatment for Disease Modification in Chronic Neurodegeneration (2021) (9)
- Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease (2008) (9)
- Selegiline stimulates biosynthesis of cytokines interleukin-1 beta and interleukin-6. (1996) (8)
- Entacapone (2010) (8)
- Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease (2017) (8)
- Emerging approaches in Parkinson’s disease – adjunctive role of safinamide (2016) (8)
- Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease (2017) (8)
- Clinical drug research in chronic central neurodegenerative disorders (2016) (7)
- ABCB1: is there a role in the drug treatment of Parkinson’s disease? (2018) (7)
- Mood disorders in early Parkinson's disease (2004) (7)
- Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence (2021) (7)
- Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice (2022) (7)
- Levodopa Induces Synthesis of Nerve Growth Factor and Growth Hormone in Patients With Parkinson Disease (2011) (6)
- Reduction in the Free Radical Status and Clinical Benefit of Repeated Intrathecal Triamcinolone Acetonide Application in Patients With Progressive Multiple Sclerosis (2014) (6)
- What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease? (2022) (6)
- Valbenazine for the treatment of tardive dyskinesia (2017) (6)
- Anxiolytic effect of rescue remedy for psychiatric patients: a double-blind, placebo-controlled, randomized trial. (2006) (5)
- Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson’s Disease and Its Inherent Risk for Melanoma (2019) (5)
- Methyl Group–Donating Vitamins Elevate 3-O-Methyldopa in Patients With Parkinson Disease (2013) (5)
- Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson’s disease (2020) (4)
- Laboratory assessments in the course of Parkinson’s disease: a clinician’s perspective (2015) (4)
- Welcome to Neuroimmunology and Neuroinflammation: a new open access journal for neuroscience (2014) (4)
- [Nutritional aspects in Parkinson's disease: disease risk, dietary therapy and treatment of digestive tract dysfunction]. (2018) (4)
- Impact of endurance exercise on levodopa associated cortisol release and force increase in patients with Parkinson's disease (2007) (3)
- Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. (2018) (3)
- Vitamin D and Blood Parameters (2021) (3)
- An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease (2020) (3)
- Safinamide for symptoms of Parkinson's disease. (2015) (3)
- Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients (2022) (3)
- Trichophagia affects response to duodenal levodopa/carbidopa gel administration (2012) (3)
- Bound, free, and total l-dopa measurement in plasma of Parkinson’s disease patients (2019) (3)
- [Wearable Technique for the Assessment of Parkinson Symptoms: What's the Future?]. (2016) (3)
- Levodopa, placebo and rotigotine change biomarker levels for oxidative stress (2017) (3)
- Biochemical indicators for neuronal regeneration during intrathecal triamcinolone application in multiple sclerosis (2015) (2)
- Quantitative EEG Changes in Patients with Parkinson's Disease during Therapy with Rasagiline (2014) (2)
- The resurgence of neurotransmitter modulation in Parkinson’s disease with safinamide (2015) (2)
- Safinamide in the treatment of Parkinson's disease. (2020) (2)
- GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease. (2021) (2)
- Editorial Regarding: Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives (2018) (2)
- Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. (2016) (2)
- Efficacy of Parecoxib, Sumatriptan, and Rizatriptan in the Treatment of Acute Migraine Attacks (2011) (2)
- Diadochokinetic movements differ between patients with Huntington's disease and controls. (2013) (2)
- Focus on Extrapyramidal Dysfunction (2004) (2)
- Do we need a new levodopa? (2016) (2)
- Kinesiology training in patients with Parkinson’s disease: results of a pilot study (2020) (1)
- Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease (2020) (1)
- No Vitamin D Deficiency in Patients with Parkinson’s Disease (2021) (1)
- Real world studies are essential for drug therapy in Parkinson’s disease (2018) (1)
- 102. SPET evaluation of [123I]-2 β-carbomethoxy-3 β-(4-iodophenyl)-tropane ([123I]β-CIT) in patients with suspicion of Parkinsonʼs disease (1996) (1)
- NEW DEVELOPMENTS FOR PARKINSON ’ S THERAPY WITH COMT INHIBITORS This symposium took place on 22 nd September 2016 as a part of the 89 th Deutsche Gesellschaft für Neurologie ( DGN ) Congress in Mannheim , Germany (2018) (1)
- [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease]. (2020) (1)
- Selegiline for Treating Parkinson’s Disease (2019) (1)
- View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track? (2021) (1)
- Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track? (2022) (1)
- [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy]. (2007) (1)
- Continuous Subcutaneous Apomorphine Infusion Improves Severe Restless Legs Syndrome (2014) (1)
- Levodopa increases speed of alternating movements in Parkinson’s disease patients (2013) (1)
- [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]. (2008) (1)
- One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study (2016) (1)
- Cholinergic-adrenergic balance: Part 1. Relationship between central and peripheral sensitivities (1990) (1)
- Future Therapeutic Options in Parkinson's Disease (2007) (0)
- Complex motion series performance differs between previously untreated patients with Parkinson’s disease and controls (2021) (0)
- Pitfalls and possible solutions for research and development of dementia therapies (2020) (0)
- Chapter 10 – The Role of Levodopa in the Chronic Neurodegenerative Disorder – Parkinson's Disease (2007) (0)
- The role of istradefylline in the Parkinson’s disease armamentarium (2023) (0)
- Stellenwert der Catechol-O-Methyltransferase -Hemmung in der modernen Parkinson-Therapie (2011) (0)
- University of Southern Denmark Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma Leupold, Dieter; Szyc, (2019) (0)
- Fix combination of levodopa/carbidopo with entacapone in the treatment of Parkinson's disease (2004) (0)
- Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again? (2022) (0)
- Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome? (2023) (0)
- 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
- Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease (2020) (0)
- Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease (2023) (0)
- Drug therapy in patients with Parkinson’s disease (2012) (0)
- Apomorphine for the Treatment of Parkinson’s Disease (2021) (0)
- Editorial announcing PubMed indexing of Degenerative Neurological and Neuromuscular Disease (2018) (0)
- 1.304 Hyperactivity and attention deficit precede the development of Parkinson's disease symptoms (2007) (0)
- Levodopa-Related ‘ Wearing Off ’ in Parkinson ’ s Disease : Current Therapeutic Options Professor (2017) (0)
- Commentary on "Depression severity and its predictors among multiple sclerosis patients in Saudi Arabia: a cross-sectional study" (2018) (0)
- 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile (2007) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas Müller?
Thomas Müller is affiliated with the following schools:
